glp 1 agonist and depression GLP-1s: Are We Ignoring the Psychiatric Risks? Schematic illustration of monoagonists, dual

Thats the million-dollar question

Follow-up appointments are scheduled to assess response and adjust dosing as needed

So this may be another reason that we would want to consider using GLP ones in our perimenopause, menopause postmenopausal population

Dose escalation phase (titration) Tirzepatide titration (dose escalation) typically follows this schedule: Month 2: 4-6 mg once weekly Month 3: 6-8 mg once weekly Month 4: If tolerated, increase to 8-10 mg once weekly Month 5: If the dosage needs to be escalated further, increase to 10-12 mg once weekly Month 6 and onward: If the dosage needs to be escalated further, increase to 12-14 mg once weekly The maximum dosage is typically 14 mg once weekly if further glycemic control or weight loss is required

Meto covers menopause-specific metabolic care at meto.co/menopause and meto.co/perimenopause